Abstract:
:Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reconstitution post rituximab is unknown due to the lack of prospective studies in different patient cohorts. The clinical significance remains controversial; some patients have recurrent infections while others are relatively asymptomatic. The aim of this review is to describe the prevalence of hypogammaglobulinemia and the associated risk for developing severe infection, in patients with differing underlying clinical conditions treated with rituximab. This may facilitate classification and prognostication of patients who develop these conditions and identify patients who may be at high risk of developing these complications, including those who may benefit from immunoglobulin replacement therapy.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Sacco KA,Abraham RSdoi
10.2217/imt-2017-0178subject
Has Abstractpub_date
2018-06-01 00:00:00pages
713-728issue
8eissn
1750-743Xissn
1750-7448journal_volume
10pub_type
杂志文章,评审相关文献
Immunotherapy文献大全abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0042
更新日期:2020-02-01 00:00:00
abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.43
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.09.39
更新日期:2009-09-01 00:00:00
abstract::Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2019-0187
更新日期:2020-01-01 00:00:00
abstract::A 63-year-old female presented with cholestatic liver function tests in November 2016. Screening tests were negative for other causes and liver biopsy revealed primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) overlap. Ursodeoxycholic acid and azathioprine was initiated. In September 2018 she was diagn...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2019-0184
更新日期:2020-05-01 00:00:00
abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0051
更新日期:2017-09-01 00:00:00
abstract::Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0179
更新日期:2018-07-01 00:00:00
abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.5
更新日期:2012-03-01 00:00:00
abstract:AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0114
更新日期:2018-04-01 00:00:00
abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.66
更新日期:2015-01-01 00:00:00
abstract::Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.1
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.47
更新日期:2013-07-01 00:00:00
abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0217
更新日期:2021-03-01 00:00:00
abstract::Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.12.143
更新日期:2013-01-01 00:00:00
abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.43
更新日期:2010-09-01 00:00:00
abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.59
更新日期:2014-01-01 00:00:00
abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.36
更新日期:2009-07-01 00:00:00
abstract::Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0223
更新日期:2021-03-01 00:00:00
abstract::Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0160
更新日期:2021-02-01 00:00:00
abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0165
更新日期:2018-08-01 00:00:00
abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.176
更新日期:2014-01-01 00:00:00
abstract::In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.87
更新日期:2011-01-01 00:00:00
abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0154
更新日期:2020-10-01 00:00:00
abstract::Increasing evidence indicates the importance of human natural killer (NK) cells in the immune response against certain viral infections. In the present article, we summarize information on NK cell responses against several viruses and on the nature of NK cell receptor-ligand interactions involved in these responses. R...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.99
更新日期:2011-09-01 00:00:00
abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.17
更新日期:2013-04-01 00:00:00
abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0202
更新日期:2020-12-01 00:00:00
abstract::Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.85
更新日期:2010-01-01 00:00:00
abstract::Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.99
更新日期:2011-02-01 00:00:00
abstract::TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.111
更新日期:2013-10-01 00:00:00
abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.57
更新日期:2015-01-01 00:00:00